Published online before print October 17, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
,
*Department of Asthma, Allergy and Respiratory Science, King’s College London, Guy’s Hospital, London, UK; Leukocyte Biology Section, National Heart and Lung Institute, Imperial College, London, UK; and Academic Unit of Respiratory Medicine, School of Medicine and Biological Sciences, University of Sheffield, UK
@ To whom correspondence should be addressed. E-mail: Hilary.sandig{at}kcl.ac.uk.
Traditionally, PGD2 has been considered to be a proinflammatory mediator, acting via classical PG receptors, such as the PGD2 receptor (DP receptor). PGD2 is degraded rapidly in vitro and in vivo to a variety of metabolites, the majority of which was thought, until recently, to be physiologically inactive. Several "inactive" metabolites, particularly 15d-PGJ2, have been shown to have wide-ranging effects on leukocytes and other cell types, however, and a potentially important anti-inflammatory role for PGD2 has now been recognized, and the complexity of PGD2 signaling is beginning to be elucidated. PGD2 and its metabolites are biologically active over a broad concentration range, and it is intriguing that it appears that there are marked concentration-dependent variations in the consequences of signaling by these eicosanoids, which have the potential to exert pro- and anti-inflammatory effects. For example, the actions of PGD2 can influence multiple stages in the life of the mature eosinophil, from causing its release from the bone marrow to inducing its recruitment and activation and ultimately, regulating its apoptosis. This review is concerned with the diverse responses induced in leukocytes by PGD2 and its metabolites and the signaling mechanisms, which are thought to be responsible for them.
Key Words: CRTH2 • DP • 15d-PGJ2 • inflammation and allergic disease
This article has been cited by other articles:
 |
|
 |
|
  T. Coll, X. Palomer, F. Blanco-Vaca, J. C. Escola-Gil, R. M. Sanchez, J. C. Laguna, and M. Vazquez-Carrera Cyclooxygenase 2 Inhibition Exacerbates Palmitate-Induced Inflammation and Insulin Resistance in Skeletal Muscle Cells Endocrinology, February 1, 2010; 151(2): 537 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Berdnikovs, H. Abdala-Valencia, C. McCary, M. Somand, R. Cole, A. Garcia, P. Bryce, and J. M. Cook-Mills Isoforms of Vitamin E Have Opposing Immunoregulatory Functions during Inflammation by Regulating Leukocyte Recruitment J. Immunol., April 1, 2009; 182(7): 4395 - 4405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Yoon, S.-B. Jeon, I.-H. Kim, and E. J. Park Regulation of TLR2 Expression by Prostaglandins in Brain Glia J. Immunol., June 15, 2008; 180(12): 8400 - 8409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Torres, C. Paget, J. Fontaine, T. Mallevaey, T. Matsuoka, T. Maruyama, S. Narumiya, M. Capron, P. Gosset, C. Faveeuw, et al. Prostaglandin D2 Inhibits the Production of IFN-{gamma} by Invariant NK T Cells: Consequences in the Control of B16 Melanoma J. Immunol., January 15, 2008; 180(2): 783 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Poncin, A.-C. Gerard, M. Boucquey, M. Senou, P. B. Calderon, B. Knoops, B. Lengele, M.-C. Many, and I. M. Colin Oxidative Stress in the Thyroid Gland: From Harmlessness to Hazard Depending on the Iodine Content Endocrinology, January 1, 2008; 149(1): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, B. Perussia, and K. S. Campbell Prostaglandin D2 Suppresses Human NK Cell Function via Signaling through D Prostanoid Receptor J. Immunol., September 1, 2007; 179(5): 2766 - 2773. [Abstract] [Full Text] [PDF]
|
|
